ArticleBlood advances2025

Prior exposure to belantamab mafodotin influences outcomes with idecabtagene vicleucel in patients with multiple myeloma.

Bhavesh Mohan Lal et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.